Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Biopharm Stat. 2012;22(2):401–415. doi: 10.1080/10543406.2010.544437

Table 3.

Data analysis of MADIT

ICD (95% CI) Conventional (95% CI) Difference (95% CI)
Effectiveness* 3.45 yrs (3.26, 3.65) 2.65 yrs (2.34, 2.96) 0.80 yr (0.43, 1.17)

Cost (simple-weighted)* $110109 (96526, 123692) $70044 (51879, 88209) $40065 (17383, 62747)

Cost (improved)* $99548 (88786, 110,310) $72754 (56023, 89485) $26794 (6901, 46687)

ACER (simple-weighted) $31883/yr $26408/yr $5475/yr
 Fieller-normal (27801, 36121) (19290, 34198) (−3061, 14011)+
 Taylor-normal (27730, 36036) (19014, 33803) (−2773, 13723)
 Bootstrap-percentile (27962, 36140) (19992, 35088) (−4030, 13788)
 Bootstrap-normal (27716, 36050) (18801, 34015) (−3289, 14191)

ACER (improved) $28825/yr $27430/yr $1395/yr
 Fieller-normal (25603, 32173) (20799, 34746) (−6313, 9140)+
 Taylor-normal (25546, 32104) (20513, 34346) (−6259, 9049)
 Bootstrap-percentile (25568, 32099) (20753, 36503) (−7693, 8856)
 Bootstrap-normal (25587, 32063) (19723, 35137) (−7043, 9833)
*

for cost and effectiveness and their differences, normal-based formulae were used for CI.

+

for CIs for the difference of the ACERs using Fieller’s method, we used the approximate relationship of standard error = (length of the CI)/(2*1.96).

For bootstrap methods, B=1000 replicates were generated.